(NASDAQ: ALNY) Alnylam Pharmaceuticals's forecast annual revenue growth rate of 29.24% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.64%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.62%.
Alnylam Pharmaceuticals's revenue in 2025 is $2,094,795,000.On average, 11 Wall Street analysts forecast ALNY's revenue for 2025 to be $319,368,616,736, with the lowest ALNY revenue forecast at $290,722,986,918, and the highest ALNY revenue forecast at $373,399,754,715. On average, 7 Wall Street analysts forecast ALNY's revenue for 2026 to be $444,527,829,166, with the lowest ALNY revenue forecast at $370,929,770,154, and the highest ALNY revenue forecast at $588,230,370,070.
In 2027, ALNY is forecast to generate $588,321,301,617 in revenue, with the lowest revenue forecast at $462,321,778,513 and the highest revenue forecast at $839,562,584,936.